**Summary of Glanbia Half Year 2025 Results**
Glanbia PLC, the Better Nutrition company, reported resilient performance for the first half of 2025, with adjusted EPS ahead of expectations, leading to an upgrade in full-year guidance. Key highlights include
**Revenue Growth**Group revenues increased by 6.0% to $1.93 billion, driven by volume growth across Health & Nutrition (H&N) and Dairy Nutrition (DN), and sequential improvement in Performance Nutrition (PN).
**Profitability**Adjusted EPS declined by 7.5% to 63.03 $cent due to elevated whey input costs, but full-year guidance was upgraded to 130-133 $cent.
**Segment Performance**
**PN**Revenue declined by 3.8%, but Optimum Nutrition showed sequential improvement with 2% revenue growth in Q2.
**H&N**Revenue grew by 18.0%, with a 260bps increase in EBITDA margin to 19.5%.
**DN**Revenue increased by 14.1%, with a 50bps margin improvement to 9.5%.
**Strategic Updates**
Acquisition of Sweetmix, a Brazil-based nutritional premix business, to expand H&N in Latin America.
Sale of Body & Fita Benelux e-commerce business.
Transformation program targeting $50m annual savings by 2027.
**Capital Allocation**
Interim dividend increased by 10% to 17.20 โฌcent.
โฌ62.8 million returned via share buybacks.
**Outlook**Full-year adjusted EPS upgraded to 130-133 $cent, with improved PN revenue growth and H&N margins.
CEO Hugh McGuire highlighted strong execution, volume growth, and margin progression, offset by PN challenges due to whey costs. The company remains focused on disciplined capital allocation and strategic growth initiatives.
Here is a comparison of Glanbia's financials and debt year on year, presented as an HTML table:
Note: All changes are shown on a constant currency basis unless otherwise stated.
This HTML table provides a clear comparison of Glanbia's financials and debt year on year, highlighting key metrics such as revenue, EBITDA, adjusted EPS, net debt, and segment performance. The tables are formatted with borders and headers for easy readability.